Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amedisys Inc (NQ: AMED )

91.92 +0.03 (+0.03%)
Streaming Delayed Price Updated: 10:50 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amedisys Inc

< Previous 1 2 3 4 Next >
AMEDISYS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amedisys, Inc. - AMED
From Kahn Swick & Foti, LLC
Via Business Wire
Analyst Expectations for Amedisys's Future
Via Benzinga
Healthcare Giants Join Hands: Option Care Health Acquires Amedisys in a $3.6 Billion Stock Swap
Option Care Health Inc (NASDAQ: OPCH) and Amedisys Inc (NASDAQ:  
Via Benzinga
AMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amedisys, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Recap: Amedisys Q1 Earnings
Via Benzinga
Analyst Ratings for Amedisys
Via Benzinga
What 10 Analyst Ratings Have To Say About Amedisys
Via Benzinga
Preview: Amedisys's Earnings
Via Benzinga
Where Amedisys Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
Analyst Ratings for Amedisys
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
Amedisys Board of Directors Authorizes $100 Million Stock Repurchase Program
From Amedisys, Inc.
Via GlobeNewswire
Expert Ratings for Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings: 
Via Benzinga
Meta Platforms To Rally 34%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences
From Amedisys, Inc.
Via GlobeNewswire
Amedisys is Named One of the Most Responsible Companies of 2023 by Statista and Newsweek
From Amedisys, Inc.
Via GlobeNewswire
Amedisys Names Scott Ginn Acting Chief Operating Officer
From Amedisys, Inc.
Via GlobeNewswire
Amedisys Statement on CY 2023 Home Health Final Rule
From Amedisys, Inc.
Via GlobeNewswire
Mastercard To $428? Plus This Analyst Slashes PT On Intel
Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022
Upgrades 
Via Benzinga
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 111 stocks hit new 52-week lows. 
Via Benzinga
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process... 
Via Benzinga
Credit Suisse, Meta Platforms, Wolfspeed And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining more than 300 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Amedisys's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Amedisys (NASDAQ:AMED) showed a loss in earnings since Q2, totaling $25.40 million. Sales, on the other hand, increased by 0.02% to $557.99 million during Q3. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million. 
Via Benzinga
Amedisys: Q3 Earnings Insights
Amedisys (NASDAQ:AMED) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys missed estimated... 
Via Benzinga
Preview: Amedisys's Earnings
Amedisys (NASDAQ:AMED) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement. Analysts estimate that Amedisys will... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.